A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.

Also called NCT01104701

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 121 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01104701
Other papers using this trial's data
  • Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial Diabetes care, 2016-10 DOI, PubMed 27436275

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01104701. Randomized; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2010-12 (actual). Results posted on 2014-07-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension
Intervention (Drug)
exenatide once weekly
Intervention (Drug)
exenatide once monthly suspension
Intervention (Drug)
exenatide once monthly suspension
Intervention (Drug)
exenatide once monthly suspension
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01104701
Content hash
3128a548692afb689aff65f93929cb335b61615c1fc0f748f14dd29406c0f962